T. D. M. Rouge

发表

Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial

I. Bièche, F. Clatot, J. Lemonnier, 2019, Annals of Oncology.

Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).

C. Genestie, I. Treilleux, I. Ray-Coquard, 2022, Gynecologic oncology.

819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

B. Monk, H. Denys, F. Heitz, 2020 .

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

J. Lemonnier, F. Bidard, M. Mouret-Reynier, 2020 .

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Abstract PD2-06: CirculatingESR1mutation detection rate and early decrease under first line aromatase inhibitor and palbociclib in the PADA-1 trial (UCBG-GINECO)

I. Bièche, J. Lemonnier, F. Bidard, 2019, Poster Discussion Abstracts.

Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) Survey.

Y. Loriot, C. Massard, H. Boyle, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

B. Escudier, Y. Loriot, K. Fizazi, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

T. Cloughesy, O. Chinot, Z. Modrušan, 2011, Advances in therapy.

[Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

I. Ray-Coquard, T. D. M. Rouge, Benoit You, 2019, Gynecologie, obstetrique, fertilite & senologie.

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

I. Treilleux, E. Kalbacher, A. Floquet, 2020, Gynecologic oncology.

Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.

C. Haie-meder, S. Culine, P. Morice, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.